SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

07 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

19 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

19 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance

07 Nov 2024 15:05:01 By Nasdaq GlobeNewswire

Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

07 Nov 2024 15:04:00 By Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

17 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

14 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

20 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

18 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Release of its First Sustainability Report

10 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

28 May 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

28 May 2024 07:30:01 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

29 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

18 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

10 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

02 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

26 Mar 2024 15:05:00 By Nasdaq GlobeNewswire